M&A Deal Summary |
|
|---|---|
| Date | 2025-10-15 |
| Target | C2 CryoBalloon |
| Sector | Medical Products |
| Buyer(s) | Merit Medical |
| Sellers(s) | PENTAX Medical Co. |
| Deal Type | Divestiture |
| Deal Value | 22M USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1987 |
| Sector | Medical Products |
| Employees | 7,400 |
| Revenue | 1.4B USD (2024) |
Merit Medical is engaged in development, manufacture and distribution of proprietary disposable medical devices used in interventional and diagnostic procedures, particularly in cardiology, radiology and endoscopy. Merit Medical was founded in 1987 and is based in South Jordan, Utah.
| DEAL STATS | # |
|---|---|
| Overall | 21 of 21 |
| Sector: Medical Products M&A | 19 of 19 |
| Type: Divestiture M&A Deals | 12 of 12 |
| State: California M&A | 4 of 4 |
| Country: United States M&A | 21 of 21 |
| Year: 2025 M&A | 2 of 2 |
| Size (of disclosed) | 11 of 16 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-05-20 |
Biolife
Sarasota, Florida, United States Biolife manufactures innovative healthcare and first-aid solutions designed to improve patient quality of life. The company's products consist of a powder with two main ingredients: potassium ferrate and a hydrophilic polymer. The products work independently of the clotting cascade to seal the wound or vascular access site while accelerating hemostasis. StatSeal products for the healthcare industry are available in powder and disc (compressed powder) form. WoundSeal products for the consumer and occupational health industries are available in powder form. Biolife is headquartered in Sarasota, Florida. |
Buy | $120M |
| Category | Company |
|---|---|
| Founded | 1979 |
| Sector | Medical Products |
PENTAX Medical Co. is a healthcare industry provider in endoscopic imaging. PENTAX Medical provides endoscopic imaging devices and solutions to the global medical community.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Medical Products M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: California M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2025 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-01-09 |
C2 CryoBalloon
Redwood City, California, United States C2 CryoBalloon is a device and related technology that delivers controlled freezing treatments to drive targeted ablation and precise destruction of unwanted soft tissue. It treats Barrett’s esophagus, as well as a less common vascular disorder, gastric antral vascular ectasia (GAVE) syndrome, by freezing and eliminating abnormal cells while still maintaining the integrity of surrounding tissue structures. C2 CryoBalloon was formed in 2007 and is based in Redwood City, California. |
Buy | - |
